Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum

Divyanshu Dubey, William S. David, Kerry L. Reynolds, Donald F. Chute, Nathan F. Clement, Justine V. Cohen, Donald P. Lawrence, Meghan J. Mooradian, Ryan J. Sullivan, Amanda C. Guidon

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Expanding use of immune-checkpoint inhibitors (ICIs) underscores the importance of accurate diagnosis and timely management of neurological immune-related adverse events (irAE-N). We evaluate the real-world frequency, phenotypes, co-occurring immune-related adverse events (irAEs), and long-term outcomes of severe, grade III to V irAE-N at a tertiary care center over 6 years. We analyze how our experience supports published literature and professional society guidelines. We also discuss these data with regard to common clinical scenarios, such as combination therapy, ICI rechallenge and risk of relapse of irAE-N, and corticosteroid taper, which are not specifically addressed by current guidelines and/or have limited data. Recommendations for management and future irAE-N reporting are outlined. ANN NEUROL 2020;87:659–669.

Original languageEnglish (US)
Pages (from-to)659-669
Number of pages11
JournalAnnals of neurology
Volume87
Issue number5
DOIs
StatePublished - May 1 2020

    Fingerprint

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Dubey, D., David, W. S., Reynolds, K. L., Chute, D. F., Clement, N. F., Cohen, J. V., Lawrence, D. P., Mooradian, M. J., Sullivan, R. J., & Guidon, A. C. (2020). Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Annals of neurology, 87(5), 659-669. https://doi.org/10.1002/ana.25708